Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.

JCI insight - 23 Jan 2025

Xu Xiongfei, Guo Shiwei, Gu Haihui, Cha Zhanshan, Shi Xiaohan, Yin Xiaoyi, Wang Huan, Gao Suizhi, Li Bo, Zhu Lingyu, Jing Wei, Zheng Kailian, Shao Zhuo, Cheng Peng, Zheng Chunhong, Shih Yi-Ping, Li Yunguang, Qian Baohua, Gao Dong, Tran Eric, Jin Gang

Abstract excerpt

T cells targeting a KRAS mutation can induce durable tumor regression in some patients with metastatic epithelial cancer. It is unknown whether T cells targeting mutant KRAS that are capable of killing tumor cells can be identified from peripheral blood of patients with pancreatic cancer. We developed an in vitro stimulation approach and identified HLA-A*11:01-restricted KRAS G12V-reactive CD8+ T cells and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4-Positive T-Lymphocytes
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to HLA-A Antigens

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptors, Antigen, T-Cell

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39846249
DOI: 10.1172/jci.insight.181873
PMCID: PMC11790028

Genes

KRAS
CD4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.PMID 39846249Read ↗

Recombinant T cell receptors specific for HLA-A*02:01-restricted neoepitopes containing KRAS codon 12 hotspot mutationsSemantic proximity Read ↗

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read ↗

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.Semantic proximity Read ↗

Adoptive T-Cell Therapy in Solid Tumor with KRASG12V/G12D MutationSemantic proximity Read ↗

Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development.Semantic proximity Read ↗

KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors.Semantic proximity Read ↗

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumorsSemantic proximity Read ↗

More T cell receptors to the RAScue in cancer?Semantic proximity Read ↗

T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial.Semantic proximity Read ↗

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsSemantic proximity Read ↗

Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells.Semantic proximity Read ↗

Clonal expansion of personalized anti-tumor T cells from circulation using tumor organoid-immune co-culturesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.